Similar articles for PMID: 30173636

Year	Number of Results
2001	1
2004	1
2005	2
2006	1
2007	2
2009	1
2012	7
2013	6
2014	12
2015	14
2016	13
2017	11
2018	9
2020	1
2024	0

1

Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations.

Fernández-Prada M, Martínez-Ortega C, Hidalgo-Peña L, Álvarez-Vázquez C, Aguirre-Del Pino R, Huerta-González I. Fernández-Prada M, et al. Farm Hosp. 2018 Sep 1;42(5):191-196. doi: 10.7399/fh.10989. Farm Hosp. 2018. PMID: 30173636 English.

2

Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study.

Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, Vipond C, Feavers I. Bryan P, et al. Lancet Child Adolesc Health. 2018 Jun;2(6):395-403. doi: 10.1016/S2352-4642(18)30103-2. Epub 2018 Apr 25. Lancet Child Adolesc Health. 2018. PMID: 30169281

3

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group. Santolaya ME, et al. Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Lancet. 2012. PMID: 22260988 Clinical Trial.

4

Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.

Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, Cultrera R, Villari P, Ricciardi W, Ioannidis JPA, Contopoulos-Ioannidis DG. Flacco ME, et al. Lancet Infect Dis. 2018 Apr;18(4):461-472. doi: 10.1016/S1473-3099(18)30048-3. Epub 2018 Jan 19. Lancet Infect Dis. 2018. PMID: 29371070

5

Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.

Carter NJ. Carter NJ. BioDrugs. 2013 Jun;27(3):263-74. doi: 10.1007/s40259-013-0029-2. BioDrugs. 2013. PMID: 23575646 Review.

6

Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.

Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Perrett KP, et al. Vaccine. 2015 Sep 22;33(39):5217-24. doi: 10.1016/j.vaccine.2015.06.103. Epub 2015 Jul 29. Vaccine. 2015. PMID: 26232542 Clinical Trial.

7

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).

Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM. Prymula R, et al. Hum Vaccin Immunother. 2014;10(7):1993-2004. doi: 10.4161/hv.28666. Hum Vaccin Immunother. 2014. PMID: 25424809 Free PMC article. Clinical Trial.

8

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.

Chiu NC, Huang LM, Willemsen A, Bhusal C, Arora AK, Reynoso Mojares Z, Toneatto D. Chiu NC, et al. Hum Vaccin Immunother. 2018 May 4;14(5):1075-1083. doi: 10.1080/21645515.2018.1425659. Epub 2018 Feb 15. Hum Vaccin Immunother. 2018. PMID: 29337653 Free PMC article. Clinical Trial.

9

Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study.

Langley JM, MacDougall DM, Halperin BA, Swain A, Halperin SA, Top KA, McNeil SA, MacKinnon-Cameron D, Marty K, De Serres G, Dubé E, Bettinger JA. Langley JM, et al. Vaccine. 2016 Jul 25;34(34):4046-9. doi: 10.1016/j.vaccine.2016.06.025. Epub 2016 Jun 11. Vaccine. 2016. PMID: 27302338

10

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Vesikari T, et al. Lancet. 2013 Mar 9;381(9869):825-35. doi: 10.1016/S0140-6736(12)61961-8. Lancet. 2013. PMID: 23324563 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

73 results

Results by year